CME ACTIVITY NO. IN08-009
Therapeutic Strategies for Antiretroviral Treatment Experienced Patients: A Case Based Update - Internet
2008
Participant Information
First Name
Last Name Degree
Address
City, State, Zip
Telephone Fax
E-Mail (CME Certificate sent by E-Mail)
Rush Medical College Alumnus Year of Graduation
______Indicate the number of credits that you are requesting for this educational activity. You should claim only credit commensurate with the extent of your participation in the activity.
Please evaluate the level of achievement of this CME activity. Match the number on the right to the questions, and fill in the appropriate circle, using a #2 pencil, according to the following scale:
5 = Excellent 4 = Good 3 = Fair 2 = Poor 1 = Unsatisfactory
Rate each faculty member on his/her content, presentation, audio/visuals, and syllabus.
Content Presentation A/V Syllabus
Calvin Cohen, MD 1. 2. 3. 4.
Evaluate how well this activity addressed the stated objectives.
5. Describe the effective use of currently approved ARVs in treatment-experienced patients.
6. Discuss recent clinical trial data on new ARV agents, including those from existing and novel classes.
7. Describe the benefits, risks and alternatives regarding the use of newer therapies in ARV-experienced patients.
8. Discuss the issues surrounding the timing for starting a new regimen or therapy in ARV-experienced patients.
9. Describe the connection between the risks associated with low-level viremia and development of resistance.
Please use the following scale to respond to the following questions:
Agree Disagree
5 4 3 2 1
In thinking about implementing these objectives, rate the following:
10. My patient mix is appropriate for the strategies.
11. My office and practice systems can accommodate these changes.
12. My patients will have trouble complying with these changes/strategies.
13. These changes are too time consuming.
14. I am so comfortable with my current approach it will be difficult to change.
15. My current office and practice systems are very difficult to change.
16. The medications/procedures discussed are not available for my patients.
In thinking about the issues raised in this educational activity, rate your degree of agreement with each statement below:
17. On average, I utilized the patient care/treatment strategies described in this educational activity prior to my participation in this educational activity.
18. I plan to implement the patient care/treatment strategies described.
19. This CME activity was free of commercial bias for or against any product. If you perceived any bias please provide specific comments below.
20. The course satisfied your reason for taking it.
21. The course was well organized and presented.
22. Please comment on the strengths/weaknesses of this activity; future topics, improvements, etc.
______
5 = Excellent 4 = Good 3 = Fair 2 = Poor 1 = Unsatisfactory
Rate each faculty member on his/her content, presentation, audio/visuals, and syllabus.
Content Presentation A/V Syllabus
Graeme Moyle, MD 23. 24. 25. 26.
July, 2007
THERAPEUTIC STRATEGIES FOR ANTIRETROVIRAL EXPERIENCED PATIENTS:
LATE FAILURE
1. Due to high barriers to resistance of newer ARVs, adding one drug onto a failing regimen is likely to lead to durable virologic suppression.
a. True
b. False
2. Etavirine remains effective in patients who have only a Y181C or a K103N mutation.
a. True
b. False
3. CCR5 antagonists (eg, maraviroc) have some beneficial effects regarding decreasing HIV RNA levels even in patients with dual/mixed tropism (ie, patients who have CCR5 and CXCR4 virus present when starting therapy)
a. True
b. False
4. Significant protease inhibitor resistance has a modest impact on raltegravir activity.
a. True
b. False
5. In POWER 1 and 2, the best predictor of sustained HIV RNA suppression was:
a. An HIV RNA decrease of >1 log10 c/mL
b. Achieving an HIV RNA <400 c/mL
c. Achieving an HIV RNA <50 c/mL
d. Achieving an HIV RNA <5 c/mL
PLEASE COMPLETE THE TWO SETS OF QUESTIONS AND RETURN VIA MAIL OR FAX TO:
ViralEd
Attention: Therapeutic Strategies Program
112 Dunkard Church Road
Stockton, NJ 08559
917-591-6353 (Fax)